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Introduction
Herpes simplex virus type 1 (HSV-1) is a large, nuclear-
replicating, dsDNA virus which is the member of the alpha herpes 
virus subfamily. The viral genome has 152 kilobase (kb) packaged 
into an icosahedral capsid surrounded by a tegument layer that 
is limited by a membranous envelope constructed with viral 
glycoproteins [1,2]. Herpes virus type 1 is the most common cause 
of cold sores around the mouth and lips (fever blisters). This virus 
is transmitted through oral secretions or wounds on the skin can 
be spread through kissing or sharing objects such as toothbrushes 
or eating utensils. HSV-1 is a neurotropic agent that establishes 
latency causing a lifelong infection in sensory neuronal ganglia 
which supply the primary site of infection [3]. Prophylactic oral 
antiviral therapy reduces recurrences of herpes simplex keratitis 
(HSK) by only 40% and has no sustained benefit following its 
discontinuation [4,5]. There are three kinetic groups of proteins 
playing a role in herpes simplex virus replication: immediate 
early, early, and late. Immediate early genes activate the host cell 
transcriptional machinery [6]. The seven of early (β) genes, DNA 
polymerase (UL30), DNA binding protein (UL42 and UL29/ ICP8), 
ORI binding protein (UL9), and the helicase/primase complex (UL5, 
UL8 and UL52) have been shown to be essential in virus replication, 
while the rest of the (β) gene products play only a partial role . In 
addition to DNA polymerase activity, the U
L
30 acts as a DNA-
dependent polynucleotide synthesis, 3’-5’ exonuclease and RNase 
H [7,8].
Different treatments against Herpes simplex virus imply the 
important role to develop more effective methods for HSV-1 
infections. Because the unavailability of a cure for herpes infections, the 
expensive treatments, and the emergence of resistance are problems 
that the entire world is still facing off [9]. One of antiviral defense 
in vertebrates which includes variety of mechanisms to inhibit virus 
replication is RNA silencing pathways. Gene silencing, induced by 
RNAi, is mediated by microRNAs (mirRNA) and small interfering 
RNA (siRNA) forming Watson–Crick base pairing to a target mRNA, 
subsequently leading to its sequence-specific cleavage [10,11]. The first 
term of RNAi was used in the worm Caenorhabditiselegans to explain 
that dsRNA complementary to a particular gene was more effective 
in silencing than either strand individually [12]. Subsequent studies 
showed that silencing related with the processing of dsRNA to small 
21–23 nucleotide-duplex short-interfering RNAs (siRNAs) and that a 
dsRNA-specific endoribonuclease III, known as Dicer, was responsible 
for cleavage of dsRNA triggering the silencing machinery that produces 
siRNA fragments (19-23 bpduplexes). And also, siRNA binds to the 
RNA-induced silencing complex (RISC) leading siRNA to the mRNA 
[13]. Then, the siRNA is unwound in an ATP-dependent manner, and 
the RISC complex becomes activated. So the target mRNA is cleaved 
to 12 nucleotides from the 30-terminus of the siRNA strand. Small 
interference RNAs (siRNAs), 21-23 nucleotide long double-stranded 
RNA molecules could specifically cleave targets mRNAs [14]. The siRNA 
cleavage action is not affected by the secondary structure of mRNA and 
the efficiency of siRNA is determined by the siRNA specific properties 
[15]. This feature is in contrast with the antisense, where silencing 
is dependent on mRNA properties such as target site accessibility, 
which is determined by local mRNA confirmation [16]. The siRNA 
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Abstract
RNA interference (RNAi) is a process by which introduced small interfering RNA (siRNA) can cause the specific 
degradation of mRNA with identical sequences. In this study, we applied siRNAs targeting the UL42 gene of 
human herpes simplex virus type 1 (HSV-1), which encodes a multifunctional polypeptide that is vital for virus DNA 
replication, binding to DNA, stably associating with the virus DNA polymerase (Pol), and acting to increase the length 
of DNA chains synthesized by Pol. HeLa cell line was used for HSV 1 infection and SiRNA transfection was done 
to suppress UL-42 gene in cell culture. The decrease in titer of HSV 1 was observed by rReal Time PCR to detect 
the drop in HSV 1 DNA synthesis and translation. The inhibition rates of siRNA1 and siRNA2 on HSV-1 plaque 
formation were reported and Comparing with virus control, siRNA1 and siRNA2 reduced DNA replication HSV-1. The 
decision whether the decrease in the number of HSV-1 plaques was due to siRNA silencing expression of the UL42 
gene, a real-time PCR indicating that UL42-specific siRNAs blocked the expression of the UL42 gene significantly. 
Comparing with virus control, siRNA1 and siRNA2 reduced the expression of UL42 gene. In this study the synthetic 
siRNA silenced UL42 mRNA expression effectively and specifically and inhibited HSV-1 replication and also our data 
offer new possibilities for RNAi as a genetic tool for inhibition of HSV-1 replication.
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sequence should be 21 nt long, and the sequence should preferably be 
50 to 100 nt downstream of the start codon and the selected sequence 
site should not be in untranslated regions [17]. The selected sequence 
should carry 5’-AA (N19) UU, where N is any nucleotide in the mRNA 
sequence. So the blast searching of a respective organism ensuring the 
specificity of selected siRNA sequences on the cleavage of the target 
sequence [18]. The HSV DNA polymerase holoenzyme is a complex of 
the UL30 protein with the UL42 protein. The UL30 protein contains 
the polymerase and exonuclease activity. The polymerase accessory 
protein of the HSV-1 DNA polymerase UL42 plays an important role 
in viral replication [19]. The UL42 gene encodes a multifunctional 
polypeptide that is vital for virus DNA replication, binding to DNA, 
stably associating with the virus DNA polymerase (Pol), and acting to 
increase the length of DNA chains synthesized by Pol [20]. 
UL42 (65 kd) increases the processivity of the UL30 DNA 
polymerase activity. Functionally, the structure of UL42 protein linked 
to the C-terminal fragment of UL30 has been determined. Unusual 
direct binding of UL42 to DNA is monomer rather than toroid 
wrapping around the DNA. UL42 is capable to diffuse linear along 
DNA despite its high affinity binding to DNA [21]. The interaction 
between UL30 and UL42 is vital for viral DNA replication in vivo, and 
these communication sites have been investigated as a good target for 
antiviral elements. UL42 also interacts with cdc2 and topoisomerase 
III [22]. In this study, we mainly focused on UL42 gene of HSV-1 and 
designed only one small interfering RNA (siRNA) molecule that targets 
the mRNA of the early gene UL42 as a possible therapeutic strategy 
in herpes simplex virus (HSV) infections and the activity of HSV-1 in 
vitro evaluated after challenging with siRNA therapy.
Material and Methods
Cell culture
The effect of siRNA on the replication of HSV 1 was measured in cell 
culture. The HeLa cells were grown in the minimum essential medium 
supplemented with 5% calf serum, 100 units/ml penicillin and 100 μg/
ml streptomycin. The cells were in the same type of medium without 
antibiotics and incubated in a 5% CO2 at 37°C during transfection. 
Estimation of transfection efficiency to determine the optimal siRNA 
concentration was done in 6 well micro plate cell cultures. Confluent 
3×250 ml (75 cm2) flasks were trypsinized and cell suspensions were 
diluted 1:10, and then 400 μl of aliquots were transferred into each 
well. Before siRNA transfection, the confluent HeLa cells in 250 ml 
(75 cm2) cell culture flasks were trypsinized with 5 ml of trypsin. After 
adding 10 ml of antibiotics, the cells were centrifuged at 2000×g for 5 
minutes. The cell pellet was resuspended in 16 ml of antibiotics free 
medium. 1×105 of cell suspensions were transferred into the dishes that 
contained 2.5 ml of antibiotic free medium. The experiments carried 
out to assay the plaque forming units in the same dishes were seeded 
with the cells in 1:14 dilution to achieve 100 % of confluency at the time 
of infection and the plaque assays were done in 24 well plates. Before 
the infection, 2 ml of medium were poured to the dishes. Confluent 
cells in 250 ml (75 cm2) cell culture flasks were trypsinized with 5 ml of 
trypsin. Cell proliferation assays were carried out in 96 well plates and 
HeLa cells grown in 250 ml (75 cm2) cell culture flasks and trypsinized 
with 5 ml of trypsin. 
HSV-1 virus stock 
Initial virus stock was derived with direct swab from a woman 
with cold sore and after DNA extraction, DNA was used for Real 
time PCR for detection HSV-1 based on instruction kit (AmpliSense, 
InterLabService, Russia). After approval of positive HSV-1, the swab 
inoculated in 75 cm2 sterile flask HeLa cell line for preparation Virus 
stock. Cells were incubated in a 5% CO2 at 37°C for virus attachment and 25 ml minimum essential medium supplemented with 5% calf 
serum, 100 units/ml penicillin and 100 μg/ml streptomycin added and 
cells incubated for 48-72 hours. Following days, the harvested infected 
cells were transferred to 250 ml bottles. Virus pellets were obtained by 
spinning the bottles at 10,000 rpm for 40 minutes at 4°C. The pellet 
was resuspended in 2 ml of medium. The stock was frozen and thawed 
once and was vortexed vigorously. The stocks were stored at -70°C in 
200 μl aliquots. One aliquot was titrated to determine the virus titer of 
the stock.
Determination of virus titer
Using the Reed and Manch method, the highest dilution of virus 
(TCID50) that causes 50% of cells to show the cytopathogenic effect 
is the virus titer. The activity of the cells was measured with the MTT 
method. Viral titer determined on HeLa cells was 5.5 TCID50 which is 
calculated by Reed and Munch is equal to 10-5.5 virus/ml.
Design and labeling of siRNA
Gene sequence of UL42 of HSV 1 was achieved from NCBI web 
site with accession UL42_0819011, UL42_08190212, UL42_08161181, 
UL42_0814709, UL42_0814709, UL42_08031195, UL42_0801852, 
UL42_07520316, UL42_07510439, UL42_0750824, UL42_07491379, 
UL42_0901420, UL42_0852551, UL42_0848290, UL42_08451381, 
UL42_0842087, UL42_08391215, UL42_0835078, UL42_0831064, 
UL42_0830614, UL42_08281267, UL42_0827493, UL42_0827350, 
UL42_0825677, UL42_0824910, UL42_08211181. Ul-42 of the HSV 
1 sequences were aligned using the EMBL-EBI web tool to identify 
the homologues gene sequences (http://www.ebi.ac.uk/Tools/msa/
clustalw2/). Several homologous target sites for siRNA were identified 
for UL42 in HSV 1. Highly effective siRNA sequence was selected and 
the possible target sites and siRNA sense and antisense obtained by 
using the Integrated DNA Technologies web tool (http://eu.idtdna.
com/Scitools/Applications/RNAi). Target sites for sense and antisense 
oligonucleotides are shown in Figure 1. The siRNA sense and antisense 
oligonucletides were purchased from Vbc Biotech (VBC-Biotech 
Service GmbH) and Cy5 labeled siRNA was used to detect the optimal 
condition for the siRNA transfection. The SiRNA was labeled by Cy5 
to ensure of SiRNA entry into the cells, and it will be detectable after 4 
hours of transfection, by using a fluorescent microscope. Sequence of 
SiRNAs was shown in Table 1.
Transfection of siRNA
Cells plated 18 to 24 hours prior to transfection and the monolayer 
cell density reaches to the optimal 50% confluency at the time of 
transfection. The culture medium with serum and antibiotics is freshly 
added to each well 30-60 minutes before transfection. PepMute™ 
siRNA Transfection Reagent (Signagene Laboratories) was used as a 
 
Figure 1: Effect of siRNA transfection on HSV-1 Plaque formation in HeLa 
cells. (a) HeLa  cells were infected with HSV-1, (b) HeLa  cells were treated 
with siRNA1 in 2.5 nM , (c) HeLa  cells were treated with SiRNA2 in 2.5 nM 
(d)HeLa  cells were treated with SiRNA1 in 3.5 nM or complete treated, (f) 
HeLa  cells were treated with siN.C(Negative control for siRNA) or untreated. 
Cultures were infected with HSV-1 and plaques were counted 48 h later.
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novel peptide based siRNA delivery tool which provides more than 
95% silencing efficiency at 1 nM siRNA in variety of mammalian 
cells. To optimize the best concentration of siRNA silencing, different 
concentration 0.5-50 nM siRNA were examined and the final siRNA 
concentration was set more than 30 nM (Figure 7). For SiRNA 
transfection, 6 well microplate with more than 50% confluency HeLa 
cells were used. SiRNA transfection was performed in two ways, before 
and after infecting cells with herpes virus. 
The media removed before cells infection, and the cells washed 
two times with PBS buffer (pH=7.4), one milliliter media, 100 µl 
transfection buffer, 3.6 µl PepMute™ reagent and 0.5-50 nM siRNA 
(final concentration) were poured. To discover the maximum gene 
silencing, dilute siRNA and PepMute™ reagent with PepMute™ 
Transfection Buffer (1x) were tested. 
Re-constituting siRNA stock solution had to be at 10 μM, so 0.5 or 
5.0 μl siRNA stock solution added per well of 6-well plate to make final 
5.0 and 50 nM siRNA respectively and mixed 3.6 μl PepMute™ reagent 
by pipetting up and down. Incubation for 15 minutes at RT was done 
to let transfection complex form and after that transfection mixture 
added to the cells drop wise. Gently shacked the plate back and forth 
and returned the plate to CO2 incubator for 24 hours. For evaluation 
of silencing after infection, infected HeLa cells were inoculated with 
herpes viruses (MOI=3) and after 48 hours supernatant media 
removed and cells washed two times with PBS (pH=7.4) and the above 
steps are repeated. Gene silencing is usually measured 24-72 hours post 
transfection.
Plaque assays
To evaluate SiRNA gene silencing efficacy, HeLa cells were grown 
in 24-well plates to 80–90% confluence and then transfected with 
specific or control siRNA using PepMute™ siRNA Transfection Reagent 
(Signagene Laboratories). After 1 h, the cells were infected with 25 PFU 
of HSV-1. Cells were overlaid with 1 ml of a 1:1 mixture of NaCMC 
(50%) and DMEM (50%) without serum to allow only cell-to-cell 
spread of virus. At 48-72 h post-infection, plates were fixed with 10% 
paraformaldehyde for 2 min and then stained with 1% crystal violet for 
20 min to count the number of plaques per well and to photograph the 
monolayer. Overlapping plaques and plaques at the edge of the well 
were counted as a single plaque.
mRNA extraction 
To evaluate SiRNA gene silencing efficacy, mRNA was extracted 
from cells with or without herpes infection and SiRNA treatment. Total 
RNA was extracted by RNA easy extraction kit (Qiagen, Germany) and 
used to study the mRNA UL42 gene expression with or without gene 
silencing in different concentrations of transfected SiRNA.
DNA extraction 
To evaluate replication of HSV-1 after silencing of UL-42 gene, 
remove of supernatant and DNA was extracted from infected cells 
before and after silencing UL-42 gene. DNA was extracted with DNA 
genomic extraction kit with following instruction manual (Bioneer, 
Korea).
rReal time PCR
Reverse transcription real time PCR (rReal time PCR ) was carried 
out by using the first strand cDNA synthesis kit by Revert Aid cDNA 
synthesis kit (Thermo scientific, USA). Briefly, RNA samples were heated 
to 65°C for 10 minutes and then chilled on ice. The uniform suspension 
of bulk first-strand cDNA reaction mix was added according to the 
manufacturer’s protocol. One μl of DTT solution, and 1 μl of pd (N)6 primer (0.2 μg) were then added to the heat-denatured RNA. Samples 
were mixed properly by pipetting up and down several times and then 
incubated for 1 hour at 42°C. For Real time PCR, the QuantiTect Probe 
PCR Kit (Qiagen, Germany) used base on instruction kit. Real time 
PCR primers and probes were design for UL42 herpes virus type 1 after 
alignment of this region between all of them in EBML-EBI and as an 
internal control, eukaryotic 18s rRNA were purchased from Metabion 
company (metabion international AG ,Germany) (Table 2).
Results
Effect of siRNA transfection on HSV-1 infection
HSV-1 produces noticeable plaques on HeLa cells without serum 
at 48 h after infection which make central clearing as the virus spreads 
outward. HeLa cells were transfected with UL42-specific siRNAs 
(siRNA1, siRNA2) or negative control siN.C and then infected with 
25 PFU of HSV-1. Comparing with virus control, transfection with 
siN.C had no effect upon viral plaque formation following infection 
(P>0.05) (Figure 1). On the other hand, HSV-1 infection of HeLa 
cells transfecting with UL42-specific siRNAs produced fewer plaques 
(P<0.01). The inhibition rates of siRNA1 and siRNA2 on HSV-1 plaque 
formation were 99.5% and 89.3%, respectively (Figure 2). Also the CPE 
Name of SiRNA Sequence Position
Si N.C Sense: UUCUCCGAACGUGUCACGUdTdTAnti-sense: ACGUGACACGUUCGGAGAAdTdT
----
-----
SiRNA1 Sense: AAUCUUCUGGGGUUUCAGGAGAnti-sense: CUCCUGAAACCCCAGAAGAUU
940
962
SiRNA2 Sense: GAGCGAGCCAACAGACAGCCAGGACAntisense: GUCCUGGCUGUCUGUUGGCUCGCUC
1029
1053
Table 1: Design of siRNA targeting the UL42 gene.
Name Sequence
Ul42 -Forward CAGCTCACCAAGGTCCTTAACG
UL42-Reverse AGCAAATGTGACGCAGGTACTC
UL42-Probe FAM-CCGATAGTGCCACGCCCACCACG-TAMARA
18sRNA -Forward GGGAGGTAGTGACGAAAAATAA
18sRNA-Reverse TTGCCCTCCAATGGATCCT
18sRNA-Probe JOE- CGAGGCCCTGTAATTGGAATGAGTCCACT-TAMARA
Table 2: UL42 sequence-specific primers and probe.
Relative effect of siRNA on HSV-1 plaque formation in each group
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Figure 2: Effect of siRNA from 0 .5 to 30 nM  on plaque formation of HSV-1 in 
HeLa cell line. Data represent the mean ± SD of three plates.
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(Cytopathtic effect) results showed that no morphological changes in 
the cells were detected in titer above 3 nmol and after 12 days with one 
cell’s passage, the cells showed no CPE (Figure 3).
Effect of siRNA on the DNA replication of HSV-1
To study of the decrease in the number of HSV-1 was due to siRNA 
silencing expression of the UL42 gene, a real-time PCR analysis was 
used. The results indicated that UL42-specific siRNAs inhibited the 
DNA replication of HSV-1 considerably. Compared with virus control, 
siRNA1 and siRNA2 reduced DNA replication HSV-1 to levels that 
were 98.5% (P<0.01) and 93.2% (P<0.01) lower, respectively, than those 
illustrated in cells treated with negative control siN.C (Figure 4) and 
the activity of the cells was measured with the MTT method (Figure 5).
Effect of siRNA on the expression of the UL42 gene
To detect mRNA UL42, the Real Time PCR was done on extracted 
RNA samples and determined that from 3 nmol/ul SiRNA or higher 
titers, the UL42 gene blocked with sharp reduction in the titer. These 
experiments have the same results after six repetitions and apparently 
became clear that the target gene UL42 decomposed from 3 nmol 
or higher. Also the examination based on CPE (Cytopathtic effect) 
showed that no morphological changes in the cells were detected in 
titer above 3 nmol and after 12 days with one cell’s passage, the cells 
showed no CPE. To decide whether the decrease in the number of 
HSV-1 plaques was due to siRNA silencing expression of the UL42 
gene, a real-time PCR analysis was performed. The results indicated 
that UL42-specific siRNAs blocked the expression of the UL42 gene 
significantly. Compared with virus control, siRNA1 and siRNA2 
reduced the expression of UL42 gene to levels which were 98.3% 
(P<0.01) and 96.5% (P<0.01) lower, respectively, than those seen in 
cells treated with negative control siN.C (Figure 6).
Discussion
Despite the effect of RNAi in probing gene function and in the 
development of novel therapeutics and antivirals, there are different 
studies exploring the potential for RNAi approaches to HSV-1 but 
variable finding have been published [23]. These studies mostly have 
focused on the α and ɣ genes of HSV-1 [24]. UL42 as a β gene, is a 
well-recognized object for antiviral agents has a role in controlling 
DNA replication and regulating other enzymes in the DNA synthesis 
pathway by means of control of the nucleotide pool [21]. In our study, 
we showed that HSV-1 was liable to the RNAi pathway. The siRNA-1 
and siRNA-2 showed in HSV-1 UL42 gene silencing and a reduction 
in viral plaque formation. Since assays with infectious viruses are 
time-consuming and labor-intensive and have to be executed under 
elevated safety conditions, a simple method for the pre selection of 
active siRNA species is desirable. In this study, we designed two 21 and 
Figure 3: Effect of siRNA UL42 transfection in HeLa cell culture. A: Normal 
HeLa cell line( uninfected or transfected with siN.C), B: Treated HeLa cell line 
with siRNA1 and no effect was seen after 48 hour , C: Flourescent microscopic 
illustration for siRNA UL42 transfected  HeLa cell line, D:infected HeLa cell line 
with HSV-1 after 24 hours, E: infected HeLa cell line with HSV-1 after 48 hours, 
F: infected HeLa cell line with HSV-1 after 72 hours.
Figure 4: Effect of siRNA UL42 transfection on HSV-1 titer in each group in 30 
nM concentration of SiRNAs, during 72 hours.
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Figure 5: Effect of siRNA transfection UL42 on HeLa cell growth in each group 
in 30 nM concentration of SiRNAs, during 72 hours(MTT assay).
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27nt siRNAs to different regions on the HSV-1 UL42 mRNA, termed 
siRNA1, siRNA2, which were synthesized chemically. To facilitate 
screening of active siRNA, we constructed the reporter dye (Cy5) for 
SiRNA2 , therefore provides a simple and fair model for estimation the 
efficacy of gene silencing by analysis at the protein level by fluorescent 
microscopy. Although these two siRNAs had sequences homology to 
the HSV-1 UL42 mRNA, they differed in their efficacy for founding 
DNA catalytic Polymerase protein silencing. In several experiments, 
siRNA1 consistently restrainedUL-42 expression more efficiently than 
the others have done, showing that the difference in efficacy cannot 
be attributed solely to differences in transfection efficiency [22,25]. 
Diversity in the silencing activity of several siRNAs targeting the same 
mRNA has also been reported previously [18,19]. The reason for the 
differences in RNAi efficacy are not well understood, but has been 
supposed to be due to differences in the thermodynamic properties 
of the siRNAs as well as the secondary and tertiary RNA structure of 
the target site, which disables recognition by the siRNA and we think 
materials for transfection are important for transfection and siRNA 
entry to the cells. There was significant difference in HeLa cell line 
infected with HSV-1 when treated and untreated with siRNA, by main 
changes in the relative amounts of HSV-1 DNA synthesis, expression 
of UL42 gene and plaque formation. During the experiment, we 
designed two pairs of UL42-specific siRNA according to the same 
principles show different efficiency. The siRNA-1 is presenting better 
results than the siRNA-2. The possible reasons were: there are more 
complex mechanisms of RNAi; some protein-binding sites exist in 
target sequences, or some siRNA sequences form a stem-loop structure 
easily and prevent the combination of siRNA and mRNA; some specific 
sequences of siRNA are more unstable and vulnerable to degradation 
of RNA enzymes, which needs further research. The siRNA designed in 
accordance with our principles can achieve good transfection efficiency, 
using suitable transfection reagents. Our experiment introduced an 
effective siRNA to inhibit UL42 gene expression specifically, which 
confirmed that UL42 specific siRNA can inhibit viral replication, while 
is not harmful for host cells. This result provided a preliminary theory 
for treating HSV-1 by RNAi. Our experiment also verified that UL42 
plays an important role in viral replication and lays the foundation 
for UL42 to be a new target. Our results showed that siRNA1 could 
efficiently inhibit HSV-1 replication in serum-starved HeLa. This is 
harmonious with their finding. The evolution of siRNA-mediated 
antiviral therapy has the greatest benefit among populations infected 
with virus strains resistant to routine antivirals and in cases of severe 
or recrudescent disease. The in vitro system depicted will be enable 
us to more easily follow up further studies of SiRNA transfection and 
provides a foundation for the development of in vivo applications of 
siRNA. In vivo activity of RNAi has been demonstrated for both viral 
and host genes of mice. These data suggest that siRNA can be developed 
as a drug.
Conclusion
In our study by designing new siRNA1 and siRNA2 against UL42 
of HSV-1, the viral infection in HeLa cells stopped and the inhibition 
rates of on HSV-1 plaque formation were 99.5% and 89.3%, shown 
respectively. The sharp inhibition for DNA replication of HSV-1 
considerably reported and expression of the UL42 gene significantly 
blocked by UL42-specific siRNAs.
Acknowledgments
This work was supported by a grant from Iran University of Medical Sciences, 
Government of Iran and also we would like to thank personnel of Laboratory of 
medical virology in Kerman University of Medical Sciences.
References
1. Ingvarsdottir K, Blaho JA (2009) Role of viral chromatin structure in the 
regulation of herpes simplex virus 1 gene expression and replication. Future 
Microbiol 4: 703-712.
2. Selvarajan Sigamani S, Zhao H, Kamau YN, Baines JD, Tang L (2013) 
The structure of the herpes simplex virus DNA-packaging terminase pUL15 
nuclease domain suggests an evolutionary lineage among eukaryotic and 
prokaryotic viruses, Journal of virology 87: 7140-7148. 
3. Di Giovine P, Settembre EC, Bhargava AK, Luftig MA, Lou H, et al. (2011) 
Structure of herpes simplex virus glycoprotein D bound to the human receptor 
nectin-1. PLoS Pathog 7: e1002277.
4. Roller DG, Dollery SJ, Doyle JL, Nicola AV (2008) Structure-function analysis of 
herpes simplex virus glycoprotein B with fusion-from-without activity. Virology 
382: 207-216.
5. Neumann DM, Bhattacharjee PS, Giordani NV, Bloom DC, Hill JM (2007) In vivo 
changes in the patterns of chromatin structure associated with the latent herpes 
simplex virus type 1 genome in mouse trigeminal ganglia can be detected at 
early times after butyrate treatment, Journal of virology 81: 13248-13253. 
6. Meleddu R, Cannas V, Distinto S, Sarais G, Del Vecchio C, et al. (2014) Design, 
synthesis, and biological evaluation of 1,3-diarylpropenones as dual inhibitors 
of HIV-1 reverse transcriptase. ChemMedChem 9: 1869-1879.
Figure 6: Effect of siRNA UL42 transfection on expression UL42 gene in HeLa 
cell line in 30 nM concentration of SiRNAs after 72 hours.
Figure 7: Effect of different concentration of siRNAs on expression UL42 gene 
in HeLa cell line after 72 hours.
Citation: Mollaei HR, Monavari SH, Arabzadeh S, Shahrabadi MS, Fazlalipour M (2014) Antiviral Activity of Sirna UL42 against Herpes Simplex Virus 
Type 1 in HeLa Cell Culture. J Antivir Antiretrovir 6: 114-119. doi:10.4172/jaa.1000106
Volume 6(3): 114-119 (2014) - 119 J Antivir AntiretrovirISSN: 1948-5964 JAA, an open access journal
7. McGeoch DJ (1987) The genome of herpes simplex virus: structure, replication 
and evolution. J Cell Sci Suppl 7: 67-94.
8. Yin S, Li Y, Xia H, Zhao J, Zhang Z, et al. (2013) An improved system for the 
evaluation of antiviral compounds against herpes simplex virus type 2. J Virol 
Methods 189: 317-320.
9. Wang A, Chen F, Wang Y, Shen M, Xu Y, et al. (2013) Enhancement of antiviral 
activity of human alpha-defensin 5 against herpes simplex virus 2 by arginine 
mutagenesis at adaptive evolution sites, Journal of virology 87: 2835-2845. 
10. Romanovskaya A, Paavilainen H, Nygardas M, Bamford DH, Hukkanen V, 
et al. (2012) Enzymatically produced pools of canonical and Dicer-substrate 
siRNA molecules display comparable gene silencing and antiviral activities 
against herpes simplex virus, PloS one 7: e51019. 
11. de Souza N (2014) Off-targets in RNAi screens. Nat Methods 11: 480.
12. Billi AC, Fischer SE, Kim JK (2014) Endogenous RNAi pathways in C. elegans. 
WormBook .
13. Mollaie HR, Monavari SH, Arabzadeh SA, Shamsi-Shahrabadi M, Fazlalipour 
M, et al. (2013) RNAi and miRNA in viral infections and cancers. Asian Pac J 
Cancer Prev 14: 7045-7056.
14. Joo MK, Yhee JY, Kim SH, Kim K (2014) The potential and advances in RNAi 
therapy: Chemical and structural modifications of siRNA molecules and use of 
biocompatible nanocarriers, Journal of controlled release: official journal of the 
Controlled Release Society15: 66-100. 
15. Njoo C, Heinl C, Kuner R (2014) In vivo SiRNA transfection and gene 
knockdown in spinal cord via rapid noninvasive lumbar intrathecal injections 
in mice. J Vis Exp .
16. Qi W, Ding D, Zhu H, Lu D, Wang Y, et al. (2014) Efficient siRNA transfection 
to the inner ear through the intact round window by a novel proteidic delivery 
technology in the chinchilla. Gene Ther 21: 10-18.
17. Qing G, Weili W, Fanqin Z, Rongchang Z, Yijin L, et al. (2011) Research of 
UL54-specific siRNA on herpes simplex virus type II replication. Int J Dermatol 
50: 362-366.
18. Liu YT, Song B, Wang YL, Xu YM, Han ZQ, et al. (2010) [SiRNA targeting ICP4 
attenuates HSV-1 replication]. Bing Du Xue Bao 26: 163-169.
19. Liu JF, Guan CP, Tang X, Xu AE (2010) [Study on the inhibition effect of siRNA 
on herpes simplex virus type 2 ICP4 gene]. Zhonghua Shi Yan He Lin Chuang 
Bing Du Xue Za Zhi 24: 199-201.
20. Steinbach JM, Weller CE, Booth CJ, Saltzman WM (2012) Polymer 
nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J 
Control Release 162: 102-110.
21. Zhe R, Mei-Ying Z, Kitazato K, Kobayash N, Qin-Chang Z, et al. (2008) Effect 
of siRNA on HSV-1 plaque formation and relative expression levels of UL39 
mRNA. Arch Virol 153: 1401-1406.
22. Zhou HC, Gao YH, Shao SW, Zhang H, Zhang T (2013) Evaluation of 
transfection effectiveness using fluorescein-labelled oligonucleotides and 
entraster-R siRNA transfection into Plasmodium falciparum, Chinese journal of 
parasitology & parasitic diseases 31: 487-489. 
23. Buerkli C, Lee SH, Moroz E, Stuparu MC, Leroux JC, et al. (2014) Amphipathic 
homopolymers for siRNA delivery: probing impact of bifunctional polymer 
composition on transfection. Biomacromolecules 15: 1707-1715.
24. Nur SM, Al Amin M, Alam R, Hasan MA, Hossain MA, et al. (2013) An in silico 
approach to design potential siRNA molecules for ICP22 (US1) gene silencing 
of different strains of human herpes simplex 1, Journal of young pharmacists 
: JYP 5: 46-49. 
25. Zhou Y, Zhang C, Liang W (2014) Development of RNAi technology for targeted 
therapy - A track of siRNA based agents to RNAi therapeutics, Journal of 
controlled release: official journal of the Controlled Release Society 25: 36-46.
Citation: Mollaei HR, Monavari SH, Arabzadeh S, Shahrabadi MS, Fazlalipour 
M (2014) Antiviral Activity of Sirna UL42 against Herpes Simplex Virus Type 1 
in HeLa Cell Culture. J Antivir Antiretrovir 6: 114-119. doi:10.4172/jaa.1000106
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
•	 User	friendly/feasible	website-translation	of	your	paper	to	50	world’s	leading	languages
•	 Audio	Version	of	published	paper
•	 Digital	articles	to	share	and	explore
Special features:
•	 350	Open	Access	Journals
•	 30,000	editorial	team
•	 21	days	rapid	review	process
•	 Quality	and	quick	editorial,	review	and	publication	processing
•	 Indexing	at	PubMed	(partial),	Scopus,	EBSCO,	Index	Copernicus	and	Google	Scholar	etc
•	 Sharing	Option:	Social	Networking	Enabled
•	 Authors,	Reviewers	and	Editors	rewarded	with	online	Scientific	Credits
•	 Better	discount	for	your	subsequent	articles
Submit	your	manuscript	at:	http://www.editorialmanager.com/virology
